The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)
Open accessAbstract
// Krzysztof M. Zak 1,2 , Przemyslaw Grudnik 2 , Katarzyna Guzik 3 , Bartosz J. Zieba 1,3 , Bogdan Musielak 3 , Alexander Dömling 4 , Grzegorz Dubin 1,2 and Tad A. Holak 1,3,5 1 Malopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa, Krakow, Poland 2 Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa, Krakow, Poland 3 Department of Organic Chemistry, Faculty of Chemistry, Jagiellonian University, Ingardena, Krakow, Poland 4 Department for Drug Design, University of Groningen, A. Deusinglaan , Groningen, The Netherlands 5 Max Planck Institute for Biochemistry, Am Klopferspitz, Martinsried, Germany Correspondence to: Grzegorz Dubin, email: // Tad A. Holak, email: // Keywords : immunotherapy, checkpoint inhibitor, small molecule, X-ray structure Received : March 30, 2016 Accepted : March 31, 2016 Published : April 13, 2016 Abstract Targeting the PD-1/PD-L1 immunologic checkpoint with monoclonal antibodies has provided unprecedented results in cancer treatment in the recent years. Development of chemical inhibitors for this pathway lags the antibody development because of insufficient structural information. The first nonpeptidic chemical inhibitors that target the PD-1/PD-L1 interaction have only been recently disclosed by Bristol-Myers Squibb. Here, we show that these small-molecule compounds bind directly to PD-L1 and that they potently block PD-1 binding. Structural studies reveal a dimeric protein complex with a single small molecule which stabilizes the dimer thus occluding the PD-1 interaction surface of PD-L1s. The small-molecule interaction “hot spots” on PD-L1 surfaces suggest approaches for the PD-1/PD-L1 antagonist drug discovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
REFMAC 5 for the refinement of macromolecular crystal structures
Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M. D., Long, F., & Vagin, A. A. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911001314 · Cited by 8,317
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 2×
“Objective responses were observed in melanoma, NSCLC and certain other solid tumors in the phase I clinical trial evaluating monoclonal antibody BMS-936559 (MDX1105) [9].”
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Scaling and assessment of data quality
Evans, P. (2006) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444905036693 · Cited by 4,374
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Niesen, F. H., Berglund, H., & Vedadi, M. (2007) · Nature Protocols · doi:10.1038/nprot.2007.321 · Cited by 2,408
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Powles, T., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Bellmunt, J., Burris, H. A., Petrylak, D. P., Teng, S.-L., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,381
Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324
Discovering High-Affinity Ligands for Proteins: SAR by NMR
Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,041
A Hot Spot of Binding Energy in a Hormone-Receptor Interface
Clackson, T., & Wells, J. A. (1995) · Science · doi:10.1126/science.7529940 · Cited by 1,983
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705
Moriarty, N. W., Grosse-Kunstleve, R. W., & Adams, P. D. (2009) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909029436 · Cited by 1,330
Combination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality
Arkin, M. R., Tang, Y., & Wells, J. A. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.001 · Cited by 1,065
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
Ohaegbulam, K. C., Assal, A., Lazar-Molnar, E., Yao, Y., & Zang, X. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.10.009 · Cited by 843
Sunshine, J., & Taube, J. M. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.05.011 · Cited by 560
Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
Zak, K. M., Kitel, R., Przetocka, S., Golik, P., Guzik, K., Musielak, B., Dömling, A., Dubin, G., & Holak, T. A. (2015) · Structure · doi:10.1016/j.str.2015.09.010 · Cited by 531
Self-citationMatulis, D., Kranz, J. K., Salemme, F. R., & Todd, M. J. (2005) · Biochemistry · doi:10.1021/bi048135v · Cited by 495
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
Lin, D. Y.-W., Tanaka, Y., Iwasaki, M., Gittis, A. G., Su, H.-P., Mikami, B., Okazaki, T., Honjo, T., Minato, N., & Garboczi, D. N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712278105 · Cited by 457
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
Shin, D. S., & Ribas, A. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.006 · Cited by 346
Structure and Interactions of the Human Programmed Cell Death 1 Receptor
Cheng, X., Veverka, V., Radhakrishnan, A., Waters, L. C., Muskett, F. W., Morgan, S. H., Huo, J., Yu, C., Evans, E. J., Leslie, A. J., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.448126 · Cited by 323
XDSAPP: a graphical user interface for the convenient processing of diffraction data using XDS
Krug, M., Weiss, M. S., Heinemann, U., & Mueller, U. (2012) · Journal of Applied Crystallography · doi:10.1107/s0021889812011715 · Cited by 306
Mueller, U., Förster, R., Hellmig, M., Huschmann, F. U., Kastner, A., Malecki, P., Pühringer, S., Röwer, M., Sparta, K., Steffien, M., et al. (2015) · The European Physical Journal Plus · doi:10.1140/epjp/i2015-15141-2 · Cited by 299
de Beer, T. A. P., Berka, K., Thornton, J. M., & Laskowski, R. A. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt940 · Cited by 299
Chalcone Derivatives Antagonize Interactions between the Human Oncoprotein MDM2 and p53
Stoll, R., Renner, C., Hansen, S., Palme, S., Klein, C., Belling, A., Zeslawski, W., Kamionka, M., Rehm, T., Mühlhahn, P., et al. (2001) · Biochemistry · doi:10.1021/bi000930v · Cited by 275
Self-citationMonitoring the Effects of Antagonists on Protein−Protein Interactions with NMR Spectroscopy
D’Silva, L., Ozdowy, P., Krajewski, M., Rothweiler, U., Singh, M., & Holak, T. A. (2005) · Journal of the American Chemical Society · doi:10.1021/ja052143x · Cited by 88
Self-citationClinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC.
Brahmer, J. R., Rizvi, N. A., Lutzky, J., Khleif, S. N., Blake-Haskins, A., Li, X., Robbins, P. B., Vasselli, J., Ibrahim, R. A., & Antonia, S. J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8021 · Cited by 78
A dimeric structure of PD-L1: functional units or evolutionary relics?
Chen, Y., Liu, P., Gao, F., Cheng, H. D., Qi, J., & Gao, G. F. (2010) · Protein & Cell · doi:10.1007/s13238-010-0022-1 · Cited by 77
Programmed Death‐1: Therapeutic Success after More than 100 Years of Cancer Immunotherapy
Dömling, A. S. S., & Holak, T. A. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307906 · Cited by 72
Self-citationKrajewski, M., Rothweiler, U., D’Silva, L., Majumdar, S., Klein, C., & Holak, T. A. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070365v · Cited by 40
Self-citationFDA approves first immunotherapy combo
Mullard, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4779 · Cited by 26
Cited by
PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
Liu, J., Chen, Z., Li, Y., Zhao, W., Wu, J., & Zhang, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.731798 · Cited by 417
Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway
Wu, Q., Jiang, L., Li, S.-C., He, Q.-J., Yang, B., & Cao, J. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0366-x · Cited by 414
Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2
Zak, K. M., Grudnik, P., Magiera, K., Dömling, A., Dubin, G., & Holak, T. A. (2017) · Structure · doi:10.1016/j.str.2017.06.011 · Cited by 388
Self-citationGuzik, K., Zak, K. M., Grudnik, P., Magiera, K., Musielak, B., Törner, R., Skalniak, L., Dömling, A., Dubin, G., & Holak, T. A. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00293 · Cited by 357
Self-citationSkalniak, L., Zak, K. M., Guzik, K., Magiera, K., Musielak, B., Pachota, M., Szelazek, B., Kocik, J., Grudnik, P., Tomala, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20050 · Cited by 294
Self-citation
Metadata
- Authors
- Zak, K. M., Grudnik, P., Guzik, K., Zieba, B. J., Musielak, B., Dömling, A., Dubin, G., & Holak, T. A.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-04-13
- Volume
- 7
- Issue
- 21
- Pages
- 30323-30335
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2338150527
- Cited by
- 422
- References
- 38
- FWCI
- 13.91
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.